Saturday, June 20, 2026

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,771
Drugs linked 4,798

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 426 of 1,261
  1. US 10640566

    Nucleic acid molecules encoding antibodies to the human glucagon receptor

    REGENERON PHARMACEUTICALS, INC. · Granted May 5, 2020 · Expires Apr 30, 2040

    granted
  2. US 10640558

    Anti-IL-25 antibodies and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted May 5, 2020 · Expires Apr 30, 2040

    granted
  3. US 10640535

    Identification of MHC class I phospho-peptide antigens from breast cancer utilizing SHLA technology and complementary enrichment strategies

    The Board of Regents of the University of Oklahoma · Granted May 5, 2020 · Expires Apr 30, 2040

    granted
  4. US 10640511

    Hepatitis B antiviral agents

    Enanta Pharmaceuticals, Inc. · Granted May 5, 2020 · Expires Apr 30, 2040

    granted
  5. US 10640534

    Therapeutically active compositions and their methods of use

    Agios Pharmaceuticals, Inc. · Granted May 5, 2020 · Expires Apr 30, 2040

    granted
  6. US 10639272

    Methods for delivering etanercept preparations into a lumen of the intestinal tract using a swallowable drug delivery device

    Rani Therapeutics, LLC · Granted May 5, 2020 · Expires Apr 30, 2040

    granted
  7. US 10639360

    Methods for treating hypophosphatemic disorders

    Ultragenyx Pharmaceutical Inc. · Granted May 5, 2020 · Expires Apr 30, 2040

    granted
  8. US 10640487

    Solid state forms of Nilotinib salts

    Teva Pharmaceuticals USA, Inc. · Granted May 5, 2020 · Expires Apr 30, 2040

    granted
  9. US 10640485

    Methods and compounds for restoring mutant p53 function

    PMV PHARMACEUTICALS, INC. · Granted May 5, 2020 · Expires Apr 30, 2040

    granted
  10. US 10639375

    Progesterone formulations

    Compass Therapeutics LLC · Granted May 5, 2020 · Expires Apr 30, 2040

    granted
  11. US 10639383

    Methods and compositions for engineering immunity

    Sangamo Therapeutics, Inc. · Granted May 5, 2020 · Expires Apr 30, 2040

    granted
  12. US 10639348

    Peptides with anti-cancer activity

    IDP DISCOVERY PHARMA, S.L. · Granted May 5, 2020 · Expires Apr 30, 2040

    granted
  13. US 10639357

    Enzymes and methods for cleaving N-glycans from glycoproteins

    The Regents of the University of California · Granted May 5, 2020 · Expires Apr 30, 2040

    granted
  14. US 10639308

    sGC stimulators

    Cyclerion Therapeutics, Inc. · Granted May 5, 2020 · Expires Apr 30, 2040

    granted
  15. US 10639320

    Pharmaceutical composition comprising gold-containing agent for preventing or treating liver fibrosis or liver cirrhosis

    KOREA UNITED PHARM. INC. · Granted May 5, 2020 · Expires Apr 30, 2040

    granted
  16. US 10639302

    Use of CDK9 inhibitors to reduce cartilage degradation

    The Regents of the University of California · Granted May 5, 2020 · Expires Apr 30, 2040

    granted
  17. US 10639289

    Application of neuraminidase and inhibitors thereof in myocardial ischemia and myocardial infarction

    CHINA PHARMACEUTICAL UNIVERSITY · Granted May 5, 2020 · Expires Apr 30, 2040

    granted
  18. DE 202020000818

    Mittel zur äußeren Pflege der Haut von Tieren, insbesondere von Pferden

    CP PHARMA HANDELSGESELLSCHAFT MBH [DE] · Granted May 4, 2020 · Expires Apr 29, 2040

    granted
  19. US 2020131224

    Methods for Synthesis of Radionuclide Complex

    ADVANCED ACCELERATOR APPLICATIONS ITALY S R L [IT] · Granted Apr 30, 2020 · Expires Apr 25, 2040

    granted
  20. US 10633657

    Methods for treatment of polycystic kidney disease

    The Board of Regents of the University of Texas System · Granted Apr 28, 2020 · Expires Apr 23, 2040

    granted
  21. US 10632194

    Anti-ErbB3 antibodies and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 28, 2020 · Expires Apr 23, 2040

    granted
  22. US 10632209

    ASH1L inhibitors and methods of treatment therewith

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Apr 28, 2020 · Expires Apr 23, 2040

    granted
  23. US 10633432

    VC-CAR molecule and use thereof in removing HIV-1 infected cells

    Shenzhen City of Regeneration Biological Pharmaceutical Technology Co., Ltd. · Granted Apr 28, 2020 · Expires Apr 23, 2040

    granted
  24. US 10633654

    Modified RNAi polynucleotides and uses thereof

    Phio Pharmaceuticals Corp. · Granted Apr 28, 2020 · Expires Apr 23, 2040

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.